Archive · 28 Sep 2026
Brokerages Split Over PB Fintech’s Insurance Commission Outlook
PB Fintech runs Policybazaar, a platform that helps people buy insurance.
Insurance companies pay the platform commissions for distributing their products.
India’s insurance regulator has proposed rules that could reduce some of these commissions.
Ambit Capital says this could hurt PB Fintech’s profits quickly and force the company to reduce costs.
It still rates the shares Buy because lower commissions could hurt competing sales channels more severely.
BofA Global Research is more optimistic about the company’s longer-term growth.
It says renewals are growing faster than new insurance sales and cost less to acquire.
BofA also sees potential in PB Partners, international operations and reinsurance broking.
However, BofA remains Neutral because the final commission rules are uncertain.
Ambit Capital retained its Buy rating and Rs 2,305 target price for PB Fintech despite expecting major pressure from proposed IRDAI commission rules.
Ambit estimates the reforms could reduce PB Fintech’s blended commission rate by about 40% in FY28 and push adjusted EBITDA near break-even.
BofA Global Research kept a Neutral rating but raised its target price to Rs 1,970 after increasing FY28 and FY29 earnings estimates.
BofA expects renewals, which carry lower acquisition costs, to grow faster than new insurance business and support long-term profitability.
Both brokerages identify regulatory uncertainty as the key near-term issue, although Ambit emphasizes immediate pressure while BofA focuses on longer-term growth.
- Who
- PB Fintech, Policybazaar’s parent company, and analysts at Ambit Capital and BofA Global Research.
- What
- Brokerages issued differing assessments of PB Fintech after proposed insurance distribution reforms could reduce commission rates.
- When
- In the latest brokerage assessments covering FY28 and FY29 estimates.
- Where
- In the Indian insurance distribution market.
- Why
- The proposed IRDAI framework could lower insurance commissions, while PB Fintech’s renewal growth and newer businesses may support longer-term earnings.
Near-Term Regulatory Pressure
Long-Term Operating Growth
Effect of proposed commission caps
Near-Term Regulatory Pressure
Ambit says the proposed caps could materially reduce commission income, make the current cost structure unsustainable and push adjusted EBITDA close to break-even in FY28.
Long-Term Operating Growth
BofA acknowledges regulatory uncertainty but gives greater weight to stronger operating momentum and raises its FY28 and FY29 earnings estimates by 7-12%.
Business economics
Near-Term Regulatory Pressure
Ambit expects health insurance commissions to face sharp pressure and says lower upfront term-insurance payouts would only be partly offset by a proposed 7.5% renewal commission.
Long-Term Operating Growth
BofA says renewals are growing faster than new business and should improve profitability because they require lower acquisition and selling costs.
Competitive impact
Near-Term Regulatory Pressure
Ambit argues that lower commissions could hurt agents, banks and non-bank financial companies more severely, potentially improving Policybazaar’s attractiveness to insurers and supporting market-share gains.
Long-Term Operating Growth
BofA focuses on the broader franchise, including PB Partners, international operations and reinsurance broking, as potential sources of longer-term growth.
- Ambit rating
- Buy
- Ambit target price
- Rs 2,305
- BofA rating
- Neutral
- BofA target price
- Rs 1,970, raised from Rs 1,800
- Estimated commission impact
- Ambit expects PB Fintech’s blended commission rate to fall about 40% in FY28 to roughly 10%.
- Renewal growth outlook
- BofA estimates renewal premiums will grow at a 39% CAGR from FY26 to FY29, versus 29% for new business.
- BofA FY28 estimates
- Revenue of Rs 12,268 crore and adjusted EBITDA of Rs 1,592 crore.